
The FDA approved giredestrant plus everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer.
Expert oncologist Giuseppe Curigliano, MD, PhD, reflects on the updated results of the HER2CLIMB study evaluating tucatinib against placebo, each in combination with trastuzumab and capecitabine, in patients with pretreated HER2+ metastatic breast cancer.
Giuseppe Curigliano, MD, PhD, discusses data from the following study:






